Diseases Treated with Stem Cells

SHARE PAGE:

Stem Cell Therapies (Current and Emerging) from Cord Blood and Cord Tissue Sources

The lifesaving power of cord blood and the regenerative healing potential of cord blood and cord tissue is no longer a secret. And, as stem cell research and treatments advance, more and more parents are motivated to bank their baby's stem cells.

Cord Blood
Cord Tissue
Primary type of stem cell population
Hematopoietic stem cells (HSCs), which create blood and immune cells
Mesenchymal stem cells (MSCs), which create connective tissue and bone
Current therapies
Transplant medicine
Used to treat more than 80 diseases, including various cancers and blood, immune, and metabolic disorders

More than 30,000 cord blood stem cell transplants performed worldwide to date
There are currently no proven therapies, but cord tissue is being evaluated in clinical trials as a therapeutic agent for optimizing hematopoietic stem cell transplantation and in regenerative medicine applications for their ability to treat various diseases and repair tissue damage.
Current research
Transplant medicine
Hundreds of clinical trials using cord blood stem cells to help advance hematopoietic stem cell transplantation

Regenerative medicine
FDA-regulated clinical trials currently evaluating the use of cord blood stem cells as a potential treatment for conditions like cerebral palsy, autism, traumatic brain injury, and pediatric stroke.

Laboratory research suggests promise across a variety of therapeutic areas including Alzheimer's disease, lung injury, heart disease, and spinal cord injury.§
Transplant medicine
The cells in the cord tissue are being evaluated for their ability to minimize transplant complications by improving engraftment rates and reducing the risk of graft versus host disease (GvHD).

Regenerative medicine
  • Growing body of pre-clinical research supports that MSCs from cord tissue have therapeutic potential for a wide range of indications
  • More than 30 clinical trials evaluating MSCs derived from cord tissue§
    • Case reports and small investigational studies indicate a preliminary positive safety profile and promising efficacy potential
    • Clinical trials evaluating cord tissue MSCs in a broad range of conditions including autoimmune disease, liver disease, orthopedic indications, and neurological conditions
Who can use them?
The newborn*
Any suitable match; siblings have a 1-in-4 chance of being a perfect match
Use will depend on the therapeutic indication.
Potentially:
The newborn
Any suitable match
Use will depend on the therapeutic indication.
Why save these stem cells?
Cord blood stem cells are used in many proven therapies today. More than 200+ clinical trials are evaluating cord blood stem cells to advance treatment options in transplant medicine and emerging regenerative applications.§ For regenerative medicine, the child's own (autologous) cord blood stem cells are usually required.
MSCs from various sources are predicted to be an integral part of new therapeutic interventions in regenerative medicine.|| Cord tissue MSCs can easily be expanded to make more cells, providing the potential for multiple clinical treatments.# With the CBR cryopreservation method, cord tissue is stored whole, preserving the full variety of cells present in cord tissue (MSCs and other cells).

*Generally, for genetic conditions, cord blood stem cells from a donor (like a sibling) may be preferable.
† Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol. 2007; 137(1):20-35.
‡ Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013.
§ clinicaltrials.gov.
|| Batsali AK, et al. Mesenchymal Stem Cells Derived from Wharton’s Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications. Current Stem Cell Research & Therapy. 2013; 8:144-155.
# Jo CH, et al. Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res. 2008 Dec; 334(3):423-433.
Cbr Systems, Inc.'s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord-derived stem cells. Cbr Systems, Inc.'s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells.